Twist Bioscience Corp (TWST) stock plummeted 5.08% in intraday trading on Tuesday, despite reporting solid first quarter fiscal 2025 results. The biotech company's revenue grew 24% year-over-year to $88.7 million, exceeding guidance, and gross margin improved to 48.3%, driven by operational efficiencies and higher revenue leverage.

However, investors appeared concerned about the company's growth prospects and outlook. During the earnings call, management acknowledged uncertainty in the academic market and challenges faced by certain customers in the cleantech and biopharma sectors due to the current economic environment.

While Twist Bioscience raised its full-year revenue guidance to $372 million to $379 million, representing growth of approximately 20% at the midpoint, the increase was primarily driven by the synthetic biology (SynBio) and biopharma services segments. The company narrowed its guidance range for the core NGS (Next-Generation Sequencing) segment, reflecting potential headwinds in this critical business area.